What the data shows
The recent diagnoses of twins Emma and Bartosz with Spinal Muscular Atrophy (SMA) raise pressing questions about the adequacy of newborn screening practices in the UK. Both children suffer from SMA type 1, the most severe form of this genetic disorder, which leads to progressive muscle weakness and mobility issues. Emma was diagnosed in 2024, while Bartosz received his diagnosis in 2021, highlighting a troubling trend of late diagnoses that can have lifelong consequences.
According to reports, all four children in the family were diagnosed late, which is particularly concerning given that late diagnosis can result in an estimated 33 UK babies needing a wheelchair due to the progression of SMA. The Scottish government has acknowledged this issue and announced that all babies will be screened for SMA as part of the NHS newborn blood spot test, a significant step in addressing the problem. However, the rollout of similar screening in England is projected for 2031, leaving many families vulnerable in the interim.
Emma and Bartosz were fortunate to receive the gene therapy Zolgensma through the NHS, a treatment that has shown promise in halting the progression of SMA and potentially eradicating it if administered early enough. This therapy represents a beacon of hope for families affected by SMA, but it also underscores the critical importance of early diagnosis. Delays in identification of the disease can severely limit the effectiveness of such interventions.
The UK remains a global outlier in terms of newborn SMA screening, with only 46 countries, including the US and nearly three-quarters of Europe, currently implementing such measures. This disparity raises questions about the healthcare system’s commitment to early detection and intervention for genetic disorders. As families like that of Emma and Bartosz navigate the challenges posed by SMA, the need for comprehensive screening becomes increasingly urgent.
In conversations with parents who have faced similar challenges, sentiments of empathy and shared experience abound. Paola and Rhys Davie, parents of children with SMA, expressed their understanding, stating, “We know how you feel.” Urszula, another parent, reflected on the overwhelming nature of the initial diagnosis, saying, “I’m sorry you’re going through this. I remember how overwhelming it felt at the beginning.” Such connections highlight the emotional toll that SMA takes on families.
Paola poignantly noted, “It’s awful to think that if I’d decided to give birth in Italy, we probably wouldn’t be having this conversation,” emphasizing the disparities in healthcare systems across countries. The emotional weight of these experiences is compounded by the knowledge that timely intervention could have made a significant difference in their children’s lives.
As Emma and Bartosz continue their journey with SMA, their story serves as a critical reminder of the importance of early diagnosis and the need for systemic changes in healthcare practices. The hope is that with increased awareness and advocacy, more families will receive the support and interventions they need at the earliest possible stage.
While the future of SMA screening in England remains uncertain, the ongoing dialogue about the necessity of early detection is vital. Families affected by SMA are left to navigate a complex landscape of healthcare, where timely access to treatment can mean the difference between mobility and lifelong challenges. As the conversation continues, the hope is that no family will have to endure the struggles faced by Emma and Bartosz due to a lack of early diagnosis.